Inhibition of Mast Cell-Derived Histamine Decreases Human Cholangiocarcinoma Growth and Differentiation via c-Kit/Stem Cell Factor-Dependent Signaling.

[1]  J. Xu,et al.  Transforming growth factor-β1-induced epithelial-mesenchymal transition generates ALDH-positive cells with stem cell properties in cholangiocarcinoma. , 2014, Cancer letters.

[2]  Yan Sun,et al.  Stem cell factor is a novel independent prognostic biomarker for hepatocellular carcinoma after curative resection. , 2014, Carcinogenesis.

[3]  H. Saya,et al.  Tumor necrosis factor‐α modulates epithelial mesenchymal transition mediators ZEB2 and S100A4 to promote cholangiocarcinoma progression , 2014, Journal of hepato-biliary-pancreatic sciences.

[4]  V. Paradis,et al.  EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. , 2014, Journal of hepatology.

[5]  G. Ranieri,et al.  Possible biological and translational significance of mast cells density in colorectal cancer. , 2014, World journal of gastroenterology.

[6]  E. Karamitopoulou,et al.  Increased Number of Non-Degranulated Mast Cells in Pancreatic Ductal Adenocarcinoma but Not in Acute Pancreatitis , 2014, International journal of immunopathology and pharmacology.

[7]  Xiaojian Wu,et al.  Tumor-Infiltrating Mast Cells in Colorectal Cancer as a Poor Prognostic Factor , 2013, International journal of surgical pathology.

[8]  Xueqiong Zhu,et al.  Role of mast cells in gynecological neoplasms. , 2013, Frontiers in bioscience.

[9]  G. Alpini,et al.  Mast cells, disease and gastrointestinal cancer: A comprehensive review of recent findings. , 2012, Translational gastrointestinal cancer.

[10]  P. Dráber,et al.  Mast Cell Chemotaxis – Chemoattractants and Signaling Pathways , 2012, Front. Immun..

[11]  R. Noelle,et al.  The roles of mast cells in anticancer immunity , 2012, Cancer Immunology, Immunotherapy.

[12]  R. Mancinelli,et al.  Histamine stimulates the proliferation of small and large cholangiocytes by activation of both IP3/Ca2+ and cAMP-dependent signaling mechanisms , 2012, Laboratory Investigation.

[13]  D. Leyva-Illades,et al.  Cholangiocarcinoma pathogenesis: Role of the tumor microenvironment. , 2012, Translational gastrointestinal cancer.

[14]  F. Meng,et al.  The H4 histamine receptor agonist, clobenpropit, suppresses human cholangiocarcinoma progression by disruption of epithelial mesenchymal transition and tumor metastasis , 2011, Hepatology.

[15]  P. Hwu,et al.  Mast Cells in Tumor Microenvironment Promotes the In Vivo Growth of Pancreatic Ductal Adenocarcinoma , 2011, Clinical Cancer Research.

[16]  Patrick Royston,et al.  Multiple imputation using chained equations: Issues and guidance for practice , 2011, Statistics in medicine.

[17]  P. Stattin,et al.  Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. , 2010, The American journal of pathology.

[18]  A. Franchitto,et al.  Secretin Inhibits Cholangiocarcinoma Growth via Dysregulation of the Camp-dependent Signaling Mechanisms of Secretin Receptor , 2022 .

[19]  G. Alpini,et al.  Recent advances in the regulation of cholangiocarcinoma growth. , 2010, American journal of physiology. Gastrointestinal and liver physiology.

[20]  E. Gaudio,et al.  Cholangiocarcinoma: update and future perspectives. , 2010, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[21]  D. Alvaro,et al.  Cholangiocarcinoma: risk factors and clinical presentation. , 2010, European review for medical and pharmacological sciences.

[22]  R. Mancinelli,et al.  H3 Histamine Receptor–Mediated Activation of Protein Kinase Cα Inhibits the Growth of Cholangiocarcinoma In vitro and In vivo , 2009, Molecular Cancer Research.

[23]  K. Khazaie,et al.  Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation. , 2009, Biochimica et biophysica acta.

[24]  R. Mancinelli,et al.  Caffeic acid phenethyl ester decreases cholangiocarcinoma growth by inhibition of NF‐κB and induction of apoptosis , 2009, International journal of cancer.

[25]  F. Redegeld,et al.  Mast cells as target in cancer therapy. , 2009, Current pharmaceutical design.

[26]  Melissa A Brown,et al.  Mast Cells , 2008, Annals of the New York Academy of Sciences.

[27]  Todd E. Bodner,et al.  What Improves with Increased Missing Data Imputations? , 2008 .

[28]  A. Franchitto,et al.  Small mouse cholangiocytes proliferate in response to H1 histamine receptor stimulation by activation of the IP3/CaMK I/CREB pathway. , 2008, American journal of physiology. Cell physiology.

[29]  I. Bachelet,et al.  Mast cells: not only in allergy. , 2006, Immunology and allergy clinics of North America.

[30]  M. Castells.  Mast cell mediators in allergic inflammation and mastocytosis. , 2006, Immunology and allergy clinics of North America.

[31]  S. Ch’ng,et al.  Mast cells and cutaneous malignancies , 2006, Modern Pathology.

[32]  Wen-Cheng Lee,et al.  Co‐expression of c‐kit and stem cell factor in primary and metastatic nasopharyngeal carcinomas and nasopharyngeal epithelium , 2005, The Journal of pathology.

[33]  F. Mascarelli,et al.  Roles of Stem Cell Factor/c-Kit and Effects of Glivec®/STI571 in Human Uveal Melanoma Cell Tumorigenesis* , 2004, Journal of Biological Chemistry.

[34]  J. Boyce.  The biology of the mast cell. , 2004, Allergy and asthma proceedings.

[35]  P. Desai,et al.  Histamine H4 Receptor Mediates Chemotaxis and Calcium Mobilization of Mast Cells , 2003, Journal of Pharmacology and Experimental Therapeutics.

[36]  J. Boyce.  Mast cells: beyond IgE. , 2003, The Journal of allergy and clinical immunology.

[37]  T. Terada,et al.  Increased mast cells in hepatocellular carcinoma and intrahepatic cholangiocarcinoma. , 2000, Journal of hepatology.

[38]  P. Welker,et al.  Altered expression of mast cell chymase and tryptase and of c-Kit in human cutaneous scar tissue. , 2000, The Journal of investigative dermatology.

[39]  F. Levi-Schaffer,et al.  The human mast cell. , 1997, The Journal of allergy and clinical immunology.

[40]  W. Gerald,et al.  Expression of c-kit and kit ligand proteins in normal human tissues. , 1994, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[41]  M. Tsai,et al.  The c-kit receptor, stem cell factor, and mast cells. What each is teaching us about the others. , 1993, The American journal of pathology.

[42]  R. Sugden.  Multiple Imputation for Nonresponse in Surveys , 1988 .

[43]  W. Dippold,et al.  Biliary adenocarcinoma. Characterisation of three new human tumor cell lines. , 1985, Journal of hepatology.